Ipsen Bioinnovation

Leading biopharmaceutical group dedicated to improving lives through innovative medicine

Ipsen is a global speciality care-driven pharmaceutical group with total sales over €2.5billion in 2020. Ipsen sells more than 20 drugs in over 115 countries, with a direct commercial presence in over 30 countries worldwide. The Group has about 5,700 employees worldwide. Ipsen’s ambition is to become a leading global biotech company focused on innovation and speciality care. Its fields of expertise cover oncology, neuroscience, and rare diseases (adult & paediatric).

Ipsen Milton Park in Oxford is home to UK R&D functions and hosts about 100 employees including researchers devoted to R&D in Neuroscience, as well as other R&D professionals including regulatory affairs, pharmacovigilance, publications, to encourage innovation and foster collaboration. It is home to their technological platform for botulinum toxins and is a pioneering research and development organization with unique experience in recombinant botulinum toxin technology.